Developing joint implants that release antibiotics to prevent infections
Drug-eluting joint implants with synergistic antimicrobial release and risk stratified models of preclinical efficacy testing
This study is working on new joint implants that can slowly release antibiotics to help prevent infections after joint surgeries, making life better for the millions of people who get these implants each year.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10809703 on NIH RePORTER |
What this research studies
This research focuses on creating innovative joint implants that can release antibiotics locally to prevent and treat infections that occur after joint surgeries. By addressing the significant issue of peri-prosthetic joint infections, which affect over a million patients annually, the project aims to improve the effectiveness of joint implants. The approach involves designing a load-bearing implant that can control the release of antibiotics, potentially enhancing patient outcomes and reducing the need for invasive revision surgeries. The research will explore various drug interactions and incorporation methods to optimize the implant's performance.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing joint arthroplasty who are at risk for peri-prosthetic joint infections.
Not a fit: Patients who have already undergone joint replacement surgeries without complications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of infections following joint surgeries, leading to better recovery and quality of life for patients.
How similar studies have performed: Previous research has shown promise in using antibiotic-eluting devices, but this specific approach is novel and aims to fill a critical gap in current treatment options.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Oral, Ebru — Massachusetts General Hospital
- Study coordinator: Oral, Ebru
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.